Is it appropriate to prescribe phentermine 37.5 mg capsule to a 59‑year‑old female patient with an estimated glomerular filtration rate of 64.9 mL/min/1.73 m²?

Phentermine 37.5 mg Can Be Prescribed, But Dose Reduction to 15 mg Daily is Recommended

With an eGFR of 64.9 mL/min/1.73 m², this patient has Stage 2 CKD (mild reduction in kidney function), and while phentermine can be prescribed, the standard 37.5 mg dose is appropriate at this level of renal function—no dose adjustment is required based on FDA labeling. However, given her age (59 years) and borderline renal function, starting at 15 mg daily would be more conservative and equally effective.

FDA-Mandated Dosing by Renal Function

The FDA label provides clear guidance on phentermine dosing in renal impairment 1:

• eGFR ≥30 mL/min/1.73 m²: Standard dosing (15-37.5 mg daily) is acceptable
• eGFR 15-29 mL/min/1.73 m² (severe impairment): Maximum 15 mg daily
• eGFR <15 mL/min/1.73 m² or dialysis: Avoid use entirely

Your patient's eGFR of 64.9 mL/min/1.73 m² falls well above the threshold requiring mandatory dose reduction.

Age-Related Considerations

The FDA label specifically addresses elderly patients 1:

• Dose selection should be cautious in elderly patients, "usually starting at the low end of the dosing range"
• Elderly patients are more likely to have decreased renal function
• Phentermine is substantially excreted by the kidney, increasing risk of toxic reactions with impaired renal function

At age 59, this patient is approaching the geriatric population where starting at 15 mg daily (rather than 37.5 mg) would align with FDA recommendations for cautious dosing.

Critical Safety Screening Required

Before prescribing, you must exclude absolute contraindications 1:

• Cardiovascular disease: History of coronary artery disease, stroke, arrhythmias, heart failure, or uncontrolled hypertension
• Hyperthyroidism (untreated)
• Glaucoma
• History of drug abuse
• Agitated states
• MAO inhibitor use (within 14 days)

The 2022 AGA guidelines emphasize that phentermine should be avoided in patients with cardiovascular disease or uncontrolled hypertension, though blood pressure typically declines with phentermine-topiramate ER 2.

Monitoring Requirements

If prescribed 1:

• Renal function monitoring: Given borderline eGFR, monitor renal function periodically (every 6-12 months minimum)
• Blood pressure and heart rate: Check periodically, especially in first 12 weeks
• Timing: Administer 2 hours after breakfast; avoid late evening dosing due to insomnia risk
• Duration: FDA-approved only for short-term use (a few weeks) 1

Practical Prescribing Algorithm

1. Screen for contraindications (cardiovascular disease, hyperthyroidism, glaucoma, drug abuse history)
2. If clear: Start at 15 mg daily given age and eGFR of 64.9
3. Can increase to 30-37.5 mg if tolerated and needed for appetite control after 1-2 weeks
4. Monitor: Renal function, blood pressure, heart rate at 4-6 weeks, then every 3 months
5. Discontinue if eGFR drops below 30 mL/min/1.73 m² or cardiovascular concerns arise

Common Pitfalls to Avoid

• Don't rely on serum creatinine alone: A "normal" creatinine can mask significant GFR reduction, especially in elderly patients with reduced muscle mass 3
• Don't ignore cardiovascular risk: Lack of large cardiovascular outcome trials means caution is warranted in anyone with cardiac history 2
• Don't prescribe long-term: Phentermine is approved only for short-term use; efficacy beyond a few weeks is not established 1
• Don't combine with other weight loss agents: Safety of combination therapy is not established 1

Bottom line: Yes, you can prescribe phentermine to this patient, but start at 15 mg daily rather than 37.5 mg given her age and eGFR of 64.9, and ensure cardiovascular contraindications are excluded first.